Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)

Table 3 Spirometry endpoints (full analysis set)

Endpoint	Treatment	Baseline value, mean	Change from baseline
Endpoint	Treatment	Baseline value, mean	LS mean (95 % CI)	LS mean difference (95 % CI)
Peak IC on Day 1, L	IND/GLY	2.36	0.46 (0.42, 0.49)	0.26 (0.22, 0.30); p < 0.0001
Peak IC on Day 1, L	Placebo	2.39	0.20 (0.17, 0.24)	0.26 (0.22, 0.30); p < 0.0001
Trough IC after 21 days, L	IND/GLY	2.36	0.11 (0.07,0.16)	0.20 (0.15, 0.25); p < 0.0001
Trough IC after 21 days, L	Placebo	2.40	-0.09 (-0.13, -0.04)	0.20 (0.15, 0.25); p < 0.0001
Peak FEV₁ on Day 1, L	IND/GLY	1.57	0.34 (0.31, 0.37)	0.22 (0.19, 0.25); p < 0.0001
Peak FEV₁ on Day 1, L	Placebo	1.59	0.12 (0.09, 0.15)	0.22 (0.19, 0.25); p < 0.0001
Peak FEV₁ after 21 days, L	IND/GLY	1.57	0.42 (0.39, 0.45)	0.37 (0.33, 0.40; p < 0.0001)
Peak FEV₁ after 21 days, L	Placebo	1.59	0.05 (0.02, 0.09)	0.37 (0.33, 0.40; p < 0.0001)
Trough FEV₁ after 21 days, L	IND/GLY	1.57	0.20 (0.17, 0.23)	0.28 (0.24, 0.31); p < 0.0001
Trough FEV₁ after 21 days, L	Placebo	1.60	-0.08 (-0.11, -0.05)	0.28 (0.24, 0.31); p < 0.0001

ISSN: 1471-2466